Streamlining Population PK Modeling with Phoenix NLME & Pirana: Bridging Efficiency and Precision in Pharmacometrics [APAC Webinar]
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 Senior Director, Pharmacometric Software, Certara Keith has more than 20 years of global drug…
CertaraApril 24, 2025
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…
CertaraMarch 20, 2025
The Unrealized Potential of Advanced Modeling Methods to Inform Early Strategic Planning for Payer Reimbursement
This article explores the overlooked yet critical role of early strategic planning for payer reimbursement…
CertaraFebruary 25, 2025
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling
Today’s drug candidates are more complex than ever. But with development decisions on the line,…
CertaraFebruary 12, 2025
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies
This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…
CertaraFebruary 6, 2025
Understanding Variability in CAR-T Cell Therapy Kinetics
Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…
CertaraJanuary 23, 2025
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease
The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…
CertaraJanuary 8, 2025
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation
This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…
CertaraDecember 9, 2024
Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women
The article "Recent Applications of Pharmacometrics and Systems Pharmacology Approaches to Improve and Optimize Drug…
CertaraNovember 18, 2024
